NR1D2 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-30. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
The County of Schaumburg (not to be confused with the Principality of Schaumburg-Lippe) around the towns of Rinteln and Hessisch Oldendorf did indeed belong to the Prussian province of Hesse-Nassau until 1932, a province that also included large parts of the present state of Hesse, including the cities of Kassel, Wiesbaden and Frankfurt am Main; but in 1932 the County of Schaumburg became part of the Prussian Province of Hanover. When the Nazi Party seized power in 1933, they quickly transformed Germany into a highly centralised state and divided the entire Third Reich into Gaue which largely superseded (but did not outright replace) Germany's traditional federal system. Nevertheless, some changes to the old state and provincial borders were made in 1937, notably including the city of Cuxhaven being fully integrated into the Prussian Province of Hanover under the Greater Hamburg Act. The effect of this Nazi-era change was that in 1946, after the Third Reich had collapsed and when state of Lower Saxony was founded, only four states needed to be merged. With the exception of Bremen and the areas that were ceded to the Soviet Occupation Zone in 1945, all those areas allocated to the new state of Lower Saxony in 1946, had already been merged into the "Constituency Association of Lower Saxony" in 1920.
Bodybuilding supplements are dietary supplements commonly used by those involved in bodybuilding, weightlifting, mixed martial arts, and athletics for the purpose of facilitating an increase in lean body mass. Bodybuilding supplements may contain ingredients that are advertised to increase a person's muscle, body weight, athletic performance, and decrease a person's percent body fat for desired muscle definition. Among the most widely used are high protein drinks, pre-workout blends and caffeinated energy drinks, branched-chain amino acids (BCAA), glutamine, arginine, essential fatty acids, creatine, HMB, whey protein, ZMA, and weight loss products. Supplements are sold either as single ingredient preparations or in the form of "stacks" – proprietary blends of various supplements marketed as offering synergistic advantages.
Agents that "bind" to the toxin can reduce free or active toxin present. It is possible for this binding to be nonspecific or specific. Activated charcoal is the non-specific binding agent most frequently utilised as it has strong adsorption capacity and could prevent the toxin's enterohepatic recirculation. Chelation agents, immunotherapy, and bioscavenger therapy are examples of specific binders. Urinary alkalization or hemadsorption may improve elimination in some circumstances.
12(S)-HETE, 12(S)-HpETE, and with far less potency 12(R)-HETE reduced insulin secretion and caused apoptosis in cultured human pancreatic insulin-secreting beta cell lines and prepared pancreatic islets. TNFα, IL-1β, and IFNγ also reduced insulin secretion in cultured human pancreatic INS-1 beta cells, apparently by inducing the expression of NOX1 (NADPH oxidase 1) and thereby to the production of cell-toxic reactive oxygen species; these cytokine effects were completely dependent on 12-lipoxygenase and mimicked by 12(S)-HETE but not 12(R)-HETE. 12-lipoxygenase-knockout mice (i.e., mice genetically manipulated to remove the Alox12, i.e. 12-lipoxygenase gene, see Lipoxygenase
Sources: en.wikipedia.org
Oligosaccharides have diverse structures. The number of monosaccharides, ring size, the different anomeric stereochemistry, and the existence of the branched-chain sugars all contribute to the amazing complexity of the oligosaccharide structures. The essence of the reducing oligosaccharide synthesis is connecting the anomeric hydroxyl of the glycosyl donors to the alcoholic hydroxyl groups of the glycosyl acceptors. Protection of the hydroxyl groups of the acceptor with the target alcoholic hydroxyl group unprotected can assure regiochemical control. Additionally, factors such as the different protecting groups, the solvent, and the glycosylation methods can influence which anomer is formed.
== Types == As of 2011, 28 types of human collagen have been identified, described, and classified according to their structure. This diversity shows collagen's diverse functionality. All of the types contain at least one triple helix. Over 90% of the collagen in humans is Type I and Type III collagen.
=== Spanish === A localised edition of Edge was launched in Spain on 15 April 2006 by publisher Globus, which shares some staff from the On/Off editorial, a Globus magazine about DVD video and consumer technology, not in any way related to video games. It lacks some articles contained in the UK edition, such as the Virtua Fighter 5 story which was omitted from the corresponding Spanish edition. At the end of May 2009, a post in the official Edge Spanish forums made by the main administrator, stated that Globus was about to close its video game division, which meant the closure of the Spanish edition of Edge and NGamer. In October 2017, a new official Edge Spanish edition is released. A new number comes every two months.
Sources: en.wikipedia.org
== Products == The company's research and development activities are focused on drugs for the treatment of severe, resistant bacterial infections and life-threatening, invasive fungal diseases. Basilea's products are aimed at diseases that have so far been insufficiently treatable. The company markets the following products exclusively through licence and distribution partners: Ceftobiprole (trade name Zevtera/Mabelio) is a broad-spectrum antibiotic administered intravenously for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in adults. It has an active effect against the bacterium Staphylococcus aureus (MRSA), including methicillin-resistant strains, and against penicillin-resistant Streptococcus pneumoniae (PRSP) bacteria, as well as against gram-negative pathogens such as Enterobacteriaceae. Isavuconazole (trade name Cresemba) is an intravenous and oral antifungal agent for the treatment of patients with invasive aspergillosis and invasive mucormycosis. While Astellas is responsible for the commercialisation of Cresemba in the USA, the pharmaceutical group Pfizer covers the commercialisation in most of Europe and also distributes Cresemba in China and the Asia–Pacific (APAC) area. Basilea's distribution partner in the MENA region is Hikma Pharmaceuticals LLC; Knight Therapeutics Inc. commercialises the antifungal Cresemba in South America.
=== Transforming growth factor β (TGF-β) === In normal conditions, alveolar macrophages adhere closely to alveolar epithelial cells, thus inducing the expression of the αvβ6 integrin. Integrins are dimeric cell-surface receptors composed of alpha and beta subunits, which activates TGF-β. TGF-β is a multifunctional cytokine that modulates a variety of biological processes such as cell growth, apoptosis, extracellular matrix synthesis, inflammation, and immune responses. TGF-β tightly regulates anti-inflammatory activity by suppressing pro-inflammatory cytokine production, thereby inhibiting T-lymphocyte function. Integrins avβ6 and avβ8 sequester latent TGF-β to the cell surface, where activation can be tightly coupled to cellular responses to environmental stress in the maintenance of homeostasis; integrins also localize activated TGFβ in the vicinity of the macrophages. Normally mature TGFβ is secreted as a latent complex with its N-terminal fragment, latency-associated peptide (LAP), which inhibits its activity. The latent complex is covalently linked to the extracellular matrix by binding to latent TGF-β-binding proteins. TGF-β is activated by diverse mechanisms in the lung, ultimately involving either proteolysis or conformational alteration of the LAP. αvβ6 integrin is able to mediate activation of TGF-β by binding to TGF-β1 LAP, which serves as a ligand binding site for the integrin, and is an essential component of the TGF-β activation apparatus. Once activated, TGFβ leads to the suppression of macrophage functionality (cytokine production and phagocytosis).
This signal is known as the free induction decay (FID), and it contains the sum of the NMR responses from all the excited spins. In order to obtain the frequency-domain NMR spectrum (NMR absorption intensity vs. NMR frequency) this time-domain signal (intensity vs. time) must be Fourier transformed. Fortunately, the development of Fourier transform (FT) NMR coincided with the development of digital computers and the digital fast Fourier transform (FFT). Fourier methods can be applied to many types of spectroscopy. Richard R. Ernst was one of the pioneers of pulsed NMR and won a Nobel Prize in chemistry in 1991 for his work on Fourier Transform NMR and his development of multi-dimensional NMR spectroscopy.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.